ArticleIndian journal of pharmacology2026
Morin ameliorates lipopolysaccharide-induced acute kidney injury in rats via alteration of TLR4/NF-κB, COX-2/PGE2, and monocyte chemoattractant protein-1/CXCL1 signaling pathway.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI), a quick decline of renal function occurring over hours to days, is defined biochemically as defective filtration, abnormal retention of nitrogenous waste in the blood, and disturbances of replacement metabolism in electrolytes and water. In this study, we examined the renal protective effect of morin on lipopolysaccharide (LPS)-induced AKI in the rats and manifested the mechanism involved. MATERIALS AND
methodsIntraperitoneal administration of LPS (10 mg/kg) was used for the induction of AKI in the rats, and the rats received the oral administration of morin (5, 10, and 15 mg/kg). The body weight, renal weight, and renal index were estimated. Renal parameters, soluble receptor for advanced glycation end products (sRAGE), advanced glycation end products (AGEs), antioxidant parameter, indoxyl sulfate, inflammatory cytokines, and inflammatory parameters were estimated. The mRNA expressions were also estimated.
resultsMorin treatment improved the body weight and reduced the renal weight and renal index. Morin treatment altered the level of renal parameters (creatinine, blood urea nitrogen [BUN], and albumin); sRAGE, AGEs, antioxidant parameters (catalase [CAT], superoxide dismutase [SOD], malonaldehyde, glutathione [GSH], oxidized GSH; indoxyl sulfate [urine, serum, and renal tissue]); inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin (IL)-1α, IL-1 β, IL-2, IL-4, IL-5, IL-7, IL-10, IL-17, C-X-C motif chemokine ligand 1 (CXCL1), interferon γ, monocyte chemoattractant protein-1 (MCP-1), MCP-1α (MCP-1α), MIP-2, granulocyte macrophage colony-stimulating factor); inflammatory parameters (cyclooxygenase-2 [COX-2], prostaglandin E2 [PGE2], inducible nitric oxide synthase, transforming growth factor-β, and nuclear factor kappa-light-chain-enhancer of activated B cells [NF-κB]), respectively. Morin treatment altered the mRNA expression of kidney injury molecule-1, neutrophil gelatinase-associated lipocalin (NGAL), manganese SOD, TNF-α, IL-1 β, IL-6, CAT, MCP-1, NADPH Oxidase 4 (NOX4), and toll-like receptor 4 (TLR4).
conclusionThe result clearly showed the renal protective effect of morin against LPS induced AKI via alteration of TLR4/NF-κB, COX-2/PGE2, and MCP-1/CXCL1 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.